← Back

Wire · operational-macro

US FDA declines to approve Capricor's cell therapy for Duchenne muscular dystrophy; shares slump

Published

21 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at finance.yahoo.com →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

The US FDA has declined to approve Capricor Therapeutics' cell therapy deramiocel for Duchenne muscular dystrophy due to serious data integrity issues in clinical trials, causing the company’s shares to drop sharply.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 12 Nov 2026 and 21 Nov 2026.

◆ ◆ The Wire takeaway

The FDA’s rejection shuts down the fastest route to market for muscle disease treatments that rely on this cell therapy approach. You need to rethink your clinical evidence strategy and funding runway if your venture is betting on this therapy’s success.

◆ Coverage

7 sources · first reported 12 Nov 2026 · latest 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfdadrug-approvalbiotechcell-therapyduchenne-muscular-dystrophy